14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CVM vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin).
Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -62.7% YoY).
Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CVM vs SRZN Key Questions & Quantitative Answers
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 43.5/100 (HOLD) at $1.91 (23.0x Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRZN leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 7-period historical trajectory (FY2011 to FY2025), CVM cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.